PURPOSE: Three years of adjuvant @entity2213 therapy are recommended for @entity1 with @entity5 ( @entity5 ) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial. @entity1 AND METHODS: Eligible @entity1 had macroscopically completely excised, @entity5 with a high risk of recurrence, as determined by using the modified National Institutes of Health criteria. After surgery, the @entity1 were randomly assigned to receive @entity2213 for either 1 or 3 years. The primary objective was recurrence-free survival (RFS), and the secondary objectives included survival. RESULTS: A total of 400 @entity1 were entered onto this open-label study between February 4, 2004, and September 29, 2008. During a median follow-up of 90 months, 171 recurrences and 69 deaths were detected. @entity1 assigned to the 3-year group had longer RFS than those assigned to the 1- year group; 5-year RFS was 71.1% versus 52.3%, respectively (hazard ratio [HR], 0.60; 95% CI 0.44 to 0.81; P < .001), and survival was 91.9% versus 85.3% (HR, 0.60; 95% CI, 0.37 to 0.97; P = .036). @entity1 in the 3-year group survived longer in the subset with centrally confirmed @entity5 and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.93; P = .024). Similar numbers of @entity299 and second @entity5 were recorded in the groups. CONCLUSION: Three years of adjuvant @entity2213 therapy results in longer survival than 1 year of @entity2213 . High 5-year survival rates are achievable in @entity1 populations with high-risk @entity5 .

Adjuvant XXXX for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['GI stromal tumor', 'cancers', 'KIT-positive GIST', 'GIST'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']
@entity2213 :: (MESH:C097613,Chemical) :: ['Imatinib']
